

June 1, 2017

Atlas Antibodies Appoints John Daicic as New CEO

Atlas Antibodies, based in Stockholm, Sweden, today announces that John Daicic has been appointed new Chief Executive Officer effective August 7, replacing Marianne Hansson who will leave the company.

John Daicic joins Atlas Antibodies from his role as Acting General Manager for BioProcess Downstream Hardware at GE Healthcare in Uppsala, Sweden. John holds a PhD in Physics from the University of Melbourne in Australia and is Associate Professor in Surface Chemistry at the Royal Institute of Technology (KTH) in Stockholm. John has extensive experience from various leading roles within research and development as well as business development in the Life Science field.

“We are extremely pleased to be able to welcome John as the new CEO of Atlas Antibodies” says Mathias Uhlén, chairman of the Board of Directors and continues: “John’s background in research and long experience in marketing and business development makes him the ideal person to lead the company to the next stage of growth.”

Atlas Antibodies have since its foundation in 2006 made a journey from a start-up company to an international player with 98% of the sales in export from more than 60,000 products aimed for researchers in industry and academia. Atlas Antibodies is well recognized as number 1 in IHC, providing reproducible polyclonal antibodies to more than 10,000 customers in 60 countries. Atlas Antibodies has a great reputation in the field of research antibodies and large potential to continue increasing the market share. New products such as the QPrEST product line for protein quantification will increase the revenue growth even further.

Marianne Hansson, who now is stepping down as CEO, has been leading the company from the start and during her period the company has been rewarded multiple times for entrepreneurial achievements, including three times on the 33 list of technology companies awarded by Ny Teknik and three times Gasell winner awarded by Dagens Industri.

“On behalf of the Board of Directors, I thank Marianne Hansson for her remarkable results in setting up Atlas Antibodies, growing the business and the excellent value she has created as CEO”, says Mathias Uhlén.

"Atlas Antibodies has made outstanding progress in commercializing the tremendous output of the Human Protein Atlas program, giving the benefit of a unique offering of antibody reagents to research and industry customers globally," says John Daicic. "I'm excited to join the Atlas Antibodies team and am looking forward to working together to create further value for customers and stakeholders as the company goes into the next important stage of its development."

About Atlas Antibodies:

Atlas Antibodies started 2006 as a start-up from the Human Protein Atlas project, and has since the start successfully launched more than 60,000 products for protein research. The company was founded by researchers at the Royal Institute of Technology (KTH) in Stockholm and the Rudbeck Laboratory, Uppsala University in Uppsala to handle the production, marketing and sales of research tools developed by the Swedish-based Human Protein Atlas program. Today the company offers four product lines: Triple A Polyclonals, Precisa Monoclonals, PrEST Antigens and QPrESTs. QPrESTs are mass spectrometry standards for absolute quantification of proteins.

For more information contact:

Mathias Uhlén, Chairman of the Board of Atlas Antibodies

mathias.uhlen@scilifelab.se

Phone: +46-8-790 9987

atlasantibodies.com